|
Jul 17
|
Mirum Gains 35% in 3 Months: How Should You Play the Stock?
|
|
Jul 11
|
Exploring 3 High Growth Tech Stocks In The US Market
|
|
Jun 17
|
Liver Drug Stock Rockets 236% Amid FDA Approval As Sales Accelerate; Funds Load Up
|
|
Jun 13
|
CoreWeave Leads Four Stocks Near Buy Points; One Is Also An Nvidia Partner
|
|
Apr 14
|
Mirum’s LIVMARLI Now FDA Approved in Tablet Formulation
|
|
Feb 24
|
Mirum’s CTEXLI™ (chenodiol) Tablets Receives FDA Approval for Treatment of Cerebrotendinous Xanthomatosis (CTX)
|
|
Feb 19
|
Mirum Pharmaceuticals to Announce Fourth Quarter and Year-End 2024 Financial Results and Host Conference Call on February 26, 2025
|
|
Feb 19
|
High Growth Tech Stocks in United States to Watch
|
|
Oct 3
|
Exploring High Growth Tech Stocks In The US October 2024
|
|
Sep 6
|
Four Biotech Stocks Rally Toward Buy Points As Funds Load Up
|
|
Sep 6
|
Mirum Pharmaceuticals (MIRM) Up 4.5% Since Last Earnings Report: Can It Continue?
|
|
Aug 29
|
High Growth Tech Stocks To Watch In August 2024
|
|
Jul 31
|
Mirum Pharmaceuticals to Announce Second Quarter 2024 Financial Results and Host Conference Call on August 7, 2024
|
|
Jul 29
|
Mirum Pharmaceuticals (MIRM) Surges 7.3%: Is This an Indication of Further Gains?
|
|
Jul 25
|
Mirum’s LIVMARLI Now Approved for PFIC in Patients 12 Months and Older
|
|
Jun 18
|
Mirum (MIRM) Soars on Interim Data From Liver Disease Studies
|
|
Jun 18
|
Mirum Pharmaceuticals (MIRM) Soars 27.3%: Is Further Upside Left in the Stock?
|
|
Jun 17
|
Mirum Pharmaceuticals Advances after Reporting Positive Trial Results for Prospective Cholangitis Treatment
|
|
Jun 17
|
Mirum’s Volixibat Achieves Positive Interim Analyses in VANTAGE PBC and VISTAS PSC Studies
|
|
Jun 16
|
Mirum Pharmaceuticals to Host Investor Call to Share Interim Analysis Results from the Volixibat VANTAGE and VISTAS studies on June 17, 2024
|